# US 2012/0252047 A1 · Salicylic acid derivatives with fluorophores and method of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252047 A1
- Document ID: US20120252047A1
- Status: Published application
- Kind: A1
- Application number: 13/075,237
- Filed: 2011-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Assignees: National Taipei University of Technology
- Inventors: Sheng-Tung HUANG
- Web page: https://patentgrep.com/patent/US20120252047A1

## CPC

- C07D 265/38: [b, e]-condensed with two six-membered rings
- C07D 211/06: having no double bonds between ring members or between ring members and non-ring members
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C12Q 1/26: involving oxidoreductase
- G01N 2333/90251: with a definite EC number (1.14.13.-)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A latent fluorophore is derived from salicylic acid, and containing a fluorogenic group and a moiety represented by formula I wherein the fluorogenic group is directly linked to the moiety of formula I or indirectly linked thereto via a linkage structure. In addition, a method of preparing a latent fluorophore, a method of using the same and a kit containing the same are also introduced.

## Claims

### Claim 1

A salicylic acid derivative, comprising a fluorogenic group and a moiety represented by formula I
wherein the fluorogenic group is directly linked to the moiety of formula I or indirectly linked thereto via a linkage structure.

### Claim 2 (depends on 1)

The salicylic acid derivative according to claim 1, which has a structure as shown by any one of the following formulas:
wherein R1 is selected from H or a C1-C6 alkyl.

### Claim 3 (depends on 1)

The salicylic acid derivative according to claim 1, wherein the fluorogeic group is selected from a group consisting of:
(wherein
R2 is selected from H or CN,
R3 is selected from
(wherein each R4 is independently selected from a C1-C6 alkyl group, a benzyl group, CN or a halogen atom).

### Claim 4 (depends on 1)

The salicylic acid derivative according to claim 1, wherein the fluorogenic group is selected from coumarin or its derivatives.

### Claim 5 (depends on 1)

The salicylic acid derivative according to claim 1, which can release a fluorogenic group under catalysis of salicyate hydroxylase (SHL).

### Claim 6 (depends on 5)

The salicylic acid derivative according to claim 5, wherein the fluorescence emitted by the fluorogenic group has a wavelength above 500 nm.

### Claim 7 (depends on 6)

The salicylic acid derivative according to claim 6, wherein the fluorescence emitted by the fluorogenic group has a peak emission wavelength of 550˜650 nm.

### Claim 8

A method for preparing a latent fluorophore, comprising:
(1) providing a protected salicylic acid derivative;
(2) linking a molecule containing a fluorogenic group to the protected salicylic acid derivative; and
(3) removing the protecting group of the salicylic acid moiety in the product of the step (2) to obtain the latent fluorophore.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the protected salicylic acid derivative in the step (1) has a structure as represented by formula V:
wherein L is a leaving group.

### Claim 10 (depends on 9)

The method according to claim 9, wherein L is selected from a halogen atom, OTs or OMs.

### Claim 11 (depends on 8)

The method according to claim 8, wherein the latent fluorophore has a structure as represented by any one of the following formulas:
wherein R1 is selected from H or a C1-C6 alkyl.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the fluorogeic group is selected from a group consisting of:
(wherein
R2 is selected from H or CN,
R3 is selected from
(wherein each R4 is independently selected from a C1-C6 alkyl group, a benzyl group, CN or a halogen atom).

### Claim 13 (depends on 8)

The method according to claim 8, wherein removing the protecting group in the step (3) is performed with a strong acid.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the strong acid is trifluoroacetic acid.

### Claim 15 (depends on 3)

A method of biochemical analysis, comprising:
(1) providing a reagent comprising
salicylate hydorxylase (SHL),
a salicylic acid derivative according to claim 3, and
NADH or NADPH;
(2) adding a specimen under test to the reagent in an aerobic environment; and
(3) measuring the fluorescence of the reagent, thereby determining the amount of salicylic acid present in the reagent.

### Claim 16 (depends on 1)

A method of biochemical analysis, comprising:
(1) providing a reagent comprising
salicylate hydorxylase (SHL),
a salicylic acid derivative according to claim 1,
NAD+ or NADP+, and
a NAD+ or NADP+-dependent dehydrogenase;
(2) adding a specimen under test to the reagent in an aerobic environment; and
(3) measuring the fluorescence of the reagent, thereby determining the amount of a biochemical molecule present in the reagent.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the biochemical molecule is a substrate for the NAD+ or NADP+-dependent dehydrogenase.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the reagent further comprises a third enzyme for catalyzing formation of a substrate for the NAD+ or NADP+-dependent dehydrogenase in the presence of the biochemical molecule.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the third enzyme is hexose kinase.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the NAD+ or NADP+-dependent dehydrogenase is selected from 3-hydroxybutyric acid dehydrogenase, cholesterol dehydrogenase, glucose dehydrogenase or glucose-6-phosphate dehydrogenase.

### Claim 21 (depends on 16)

The method according to claim 16, wherein the salicylic acid derivative has a structure as represented by any one of the following formulas:
wherein R1 is selected from H or a C1-C6 alkyl.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the fluorogenic group is selected from a group consisting of:
(wherein
R2 is selected from H or CN,
R3 is selected from
(wherein each R4 is independently selected from a C1-C6 alkyl group, a benzyl group, CN or a halogen atom).

### Claim 23 (depends on 3)

A kit for biochemical analysis, comprising:
salicylate hydroxylase;
NAD+ or NAD+-dependent dehydrogenase;
NAD+ or NADP+; and
the salicylic acid derivative according to claim 3.

### Claim 24 (depends on 23)

The kit for biochemical analysis according to claim 23, which further comprising a third enzyme for catalyzing formation of a substrate for the NAD+ or NADP+-dependent dehydrogenase.
